Inovio Pharmaceuticals Stock Alpha and Beta Analysis
| INO Stock | USD 1.69 0.05 2.87% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Inovio Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Inovio Pharmaceuticals over a specified time horizon. Remember, high Inovio Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Inovio Pharmaceuticals' market risk premium analysis include:
Beta 1.06 | Alpha (0.41) | Risk 5.45 | Sharpe Ratio (0.07) | Expected Return (0.40) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Inovio Pharmaceuticals Backtesting, Inovio Pharmaceuticals Valuation, Inovio Pharmaceuticals Correlation, Inovio Pharmaceuticals Hype Analysis, Inovio Pharmaceuticals Volatility, Inovio Pharmaceuticals History and analyze Inovio Pharmaceuticals Performance. Inovio Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Inovio Pharmaceuticals market risk premium is the additional return an investor will receive from holding Inovio Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Inovio Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Inovio Pharmaceuticals' performance over market.| α | -0.41 | β | 1.06 |
Inovio Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Inovio Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Inovio Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Inovio Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Inovio Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inovio Pharmaceuticals shares will generate the highest return on investment. By understating and applying Inovio Pharmaceuticals stock market price indicators, traders can identify Inovio Pharmaceuticals position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Simple Moving Average | ||
| Parabolic SAR | ||
| Stalled Pattern | ||
| Separating Lines |
Inovio Pharmaceuticals Return and Market Media
The median price of Inovio Pharmaceuticals for the period between Tue, Oct 7, 2025 and Mon, Jan 5, 2026 is 2.25 with a coefficient of variation of 11.77. The daily time series for the period is distributed with a sample standard deviation of 0.26, arithmetic mean of 2.2, and mean deviation of 0.22. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Inovio Pharmaceuticals, Inc. Given Average Rating of Hold by Brokerages | 10/17/2025 |
2 | Shingles Vaccine Research Report 2025 Market to Reach 9.6 Billion by 2029, Driven by Aging Population, Recombinant Vaccine Innovation, and Expanding Adult Immun... | 11/04/2025 |
3 | Inovio Pharmaceuticals drops 6, proposes equity offering | 11/11/2025 |
4 | Inovio 3Q25 Review EPS Miss, 25M Offering, And INO-3107 Progress - Seeking Alpha | 11/12/2025 |
5 | Individual investors invested in Inovio Pharmaceuticals, Inc. lost 13 percent last week, institutions remained on the sidelines | 11/14/2025 |
6 | Will Inovio Pharmaceuticals Inc. stock gain from lower interest rates - Weekly Loss Report High Conviction Trade Alerts - newser.com | 11/19/2025 |
7 | Inovalis Real Estate Investment Trust Stock Price Crosses Below Two Hundred Day Moving Average Should You Sell | 11/26/2025 |
8 | INOVIOs Future Investor Insights - StocksToTrade | 12/17/2025 |
9 | Inovalis Real Estate Investment Trust Stock Price Up 17.2 percent Heres What Happened | 12/24/2025 |
10 | FDA Accepts for Review INOVIOs BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis | 12/29/2025 |
11 | Looking Into Inovio Pharmaceuticals Incs Recent Short Interest | 01/02/2026 |
About Inovio Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Inovio or other stocks. Alpha measures the amount that position in Inovio Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Dividend Yield | 0.005012 | 0.005263 | Price To Sales Ratio | 205.43 | 195.16 |
Inovio Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Inovio Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inovio Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Inovio Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Inovio Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Inovio Pharmaceuticals' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Inovio Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Inovio Pharmaceuticals Backtesting, Inovio Pharmaceuticals Valuation, Inovio Pharmaceuticals Correlation, Inovio Pharmaceuticals Hype Analysis, Inovio Pharmaceuticals Volatility, Inovio Pharmaceuticals History and analyze Inovio Pharmaceuticals Performance. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Inovio Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.